Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 77 for:    MACE, cardiovascular systems inc
Previous Study | Return to List | Next Study

Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE) (MACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01930214
Recruitment Status : Completed
First Posted : August 28, 2013
Results First Posted : April 24, 2019
Last Update Posted : April 24, 2019
Sponsor:
Information provided by (Responsible Party):
Cardiovascular Systems Inc

Brief Summary:

The objective of this study is to assess the current standard of care treatment outcome in none/mild, moderate and severely calcified coronary lesions using:

  • A composite of MACE at 30-day and one (1) year post procedure, and
  • Procedural and lesion success

Condition or disease Intervention/treatment
Coronary Artery Disease Device: Percutaneous Coronary Intervention

Detailed Description:
This prospective, non-randomized, multi-center study includes subjects who meet all of the inclusion and none of the exclusion criteria and sign the ICF. This study may treat up to approximately 500 subjects at up to 50 active sites in the U.S. Subjects may be followed up to three (3) years. Subjects will be stratified into one (1) of three (3) arms based on the degree of calcification in the coronary lesion as defined by this protocol. The duration of the study is expected to be approximately four (4) years.

Layout table for study information
Study Type : Observational
Actual Enrollment : 350 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)
Actual Study Start Date : September 26, 2013
Actual Primary Completion Date : November 7, 2016
Actual Study Completion Date : June 1, 2017

Group/Cohort Intervention/treatment
None/mild calcification
Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
Device: Percutaneous Coronary Intervention
Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Moderate Calcification
Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
Device: Percutaneous Coronary Intervention
Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Severe calcification
Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
Device: Percutaneous Coronary Intervention
Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).




Primary Outcome Measures :
  1. MACE at 30 Days [ Time Frame: 30 days post procedure ]

    A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 30 days.

    30-day MACE is composed of:

    • Cardiac death
    • Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
    • Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure


Secondary Outcome Measures :
  1. MACE at One (1) Year [ Time Frame: One (1) year post procedure ]

    A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 1 year.

    1-year MACE is composed of:

    • Cardiac death
    • Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
    • Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure

  2. Procedural Success [ Time Frame: Participants were followed from baseline procedure through hospital discharge, an expected average of 24 hours ]
    Procedural success is defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE.

  3. Lesion Success [ Time Frame: During the procedure ]
    Lesion success is defined as success in facilitating stent delivery with a post-procedural result of <50% residual stenosis for a given lesion treated during the procedure without severe angiographic complications.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
18 years or older who are scheduled for percutaneous coronary revascularization involving stent.
Criteria

Inclusion Criteria:

  1. Subjects must be at least 18 years of age.
  2. Subjects must be scheduled for percutaneous coronary revascularization involving stent deployment in de novo coronary lesions. Percutaneous coronary revascularization is defined as treatment with commercially available devices that may include but not limited to balloon angioplasty, cutting balloon, rotablation, etc. followed by the stent placement.
  3. Subjects CK-MB must be less than or equal to the upper limit of lab normal value within eight (8) hours prior to procedure. If CK-MB results are not yet available prior to initiating procedure, subjects Troponin I or Troponin T must be less than or equal to the upper limit of lab normal value within eight (8) hours prior to the procedure.
  4. The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure.
  5. The target vessel must be a native coronary artery with:

    1. A stenosis ≥ 70% and < 100%, or
    2. A stenosis ≥ 50% < 70% with evidence of clinical ischemia
  6. The target vessel reference diameter must be ≥ 2.5mm and ≤ 4.0 mm.
  7. The lesion length must not exceed 40 mm.
  8. The target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow three (3) at baseline.

Exclusion Criteria:

  1. Inability to understand the study or a history of non-compliance with medical advice.
  2. Unwilling or unable to sign the MACE clinical study ICF.
  3. History of any cognitive or mental health status that would interfere with study participation.
  4. Currently enrolled in any other pre-approval investigational study. This does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.).
  5. Female subjects who are pregnant or planning to become pregnant within the study period.
  6. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications.
  7. Known sensitivity to contrast media, which cannot be adequately pre-medicated.
  8. Diagnosed with chronic renal failure unless under hemodialysis, or has a serum creatinine level >2.5 mg/dl.
  9. History of major cardiac intervention within 30-day, not including a PCI procedure for a staging purpose.
  10. Evidence of heart failure by one of the following:

    i. Left Ventricular Ejection Fraction (LVEF) ≤ 25% ii. New York Heart Association (NYHA) class III or IV iii. Clinical symptoms

  11. History of a stroke or transient ischemic attack (TIA) within six (6) months
  12. Active peptic ulcer or upper gastrointestinal (GI) bleeding within six (6) months.
  13. History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary.
  14. Concurrent medical condition with a life expectancy of < 36 months.
  15. History of immune deficiency.
  16. Uncontrolled insulin dependent diabetes.
  17. Evidence of active infections on the day of the index procedure.
  18. Subject has planned cardiovascular intervention within 60 days post index procedure.
  19. Subject with angiographically confirmed evidence of more than two (2) lesions within one (1) vessel or more than one (1) vessel requiring intervention, unless the treatment is staged. See Section 10.1 for more details.
  20. Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or Left Internal Mammary Artery/ Right Internal Mammary Artery (LIMA/RIMA) bypass.
  21. Target vessel has angiographically visible or suspected thrombus.
  22. Target vessel appears to be/is excessively tortuous at baseline.
  23. Target lesion is an ostial location (within 5mm of ostium) or an unprotected left main lesion.
  24. Target lesion is a bifurcation (side branch ≥ 1.5mm).
  25. Treatment of the target lesion with the CSI coronary Diamondback Orbital Atherectomy System (OAS).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01930214


  Show 34 Study Locations
Sponsors and Collaborators
Cardiovascular Systems Inc
Investigators
Layout table for investigator information
Principal Investigator: Samin K Sharma, MD Icahn School of Medicine at Mount Sinai

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Cardiovascular Systems Inc
ClinicalTrials.gov Identifier: NCT01930214     History of Changes
Other Study ID Numbers: CLN-0002-P
First Posted: August 28, 2013    Key Record Dates
Results First Posted: April 24, 2019
Last Update Posted: April 24, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases